SCHEMBL4842200

SCHEMBL4842200

CCN(CC)Cc1ccc(-c2nnc(Cl)c3cc(OC)ccc23)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.42
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
ACHE P22303 5/20 0.39
MAOB P27338 4/20 0.39
ALDH1A1 P00352 2/20 0.39
LMNA P02545 1/20 0.39
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
MAOA P21397 1/20 0.38
ENPP1 P22413 1/20 0.38
KDM4E B2RXH2 1/20 0.37
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37
POLB P06746 1/20 0.37
HTR1A P08908 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4843630 0.84 PDE4A (0.45) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL4122604 0.83 PDE4A (0.47) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL4843462 0.83 ALDH1A1 (0.47) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL4834009 0.81 DHODH (0.48) PDE4APDE4BPDE4CPDE4DMAPK1
SCHEMBL4834669 0.79 HTT (0.48) PDE4APDE4BPDE4CPDE4DACHE
SCHEMBL4843388 0.78 PDE4A (0.55) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL4840257 0.78 MAPK14 (0.46) PDE4APDE4BPDE4CPDE4DMAOB
SCHEMBL4840317 0.78 PDE4A (0.46) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL4845442 0.78 PDE4A (0.57) PDE4APDE4BPDE4CPDE4DTSHR
SCHEMBL4842181 0.76 PDE4A (0.43) PDE4APDE4BPDE4CPDE4DALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7423030-B2 1-amino-phthalazine derivatives, the preparation and the therapeutic use thereof SANOFI-AVENTIS (FR) 2008-09-09 US disclosed
EP-1737840-B1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2007-09-12 EP disclosed
US-20070099895-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2007-05-03 US disclosed
EP-1737840-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2007-01-03 EP disclosed
WO-2005103033-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2005-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099895-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF CYP11B2, CYP11B1, GOT2 HRH3 1711/4885PDE4A 1615/4885PDE4B 1845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.